Cryoport announces certain preliminary results for second quarter & updates 2023 revenue expectations

Second quarter results were impacted by weaker than expected global demand for capital equipment; clinical trial start delays; and slower than expected ramps from certain clients second quarter revenue expected in the range of $56.5 - $57.5 million full year 2023 revenue now expected in the range of $233 - $243 million long-term outlook robust with cell and gene therapy industry expected to grow at a ten-year cagr in excess of 22% nashville, tenn. , july 12, 2023 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) ("cryoport" or the "company"), a leading global provider of innovative products and services for the fast growing cell and gene therapy industry, today announced certain preliminary results for second quarter 2023 and updated its expectations for full year 2023 revenue expectations.
CYRX Ratings Summary
CYRX Quant Ranking